We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 1.30% | 30.48 | 30.40 | 30.50 | 30.52 | 30.31 | 30.32 | 1,121,708 | 21:15:26 |
From May 2019 to May 2024
By Michael Dabaie
Prothena Corp. PLC shares were down 19% to $9.67 in early trading.
The clinical-stage neuroscience company said Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease.
Prothena said the study didn't meet the primary objective, but showed signals of efficacy. In 2013, Prothena and Roche entered into a collaboration to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab.
Based on ongoing evaluation of the data, including potential discussions with health authorities, a further update on prasinezumab is expected later this year.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 22, 2020 09:57 ET (13:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
